Eli Lilly’s monoclonal antibody against Covid-19 could experience slow trial recruitment despite potential efficacy

Other companies also have candidates for the prophylactic treatment of Covid-19, such as Regeneron Pharmaceuticals’ candidate antibody cocktail, REGN-COV2. Credit: Shutterstock.



  • Eli Lilly Covid-19 monoclonal antibody